

Jonathon B Cohen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3699675/publications.pdf>

Version: 2024-02-01

91
papers

3,100
citations

236833

25
h-index

161767

54
g-index

91
all docs

91
docs citations

91
times ranked

3920
citing authors

#	ARTICLE	IF	CITATIONS
1	Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1283-1294.	5.1	818
2	Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. <i>Blood</i> , 2014, 124, 2354-2361.	0.6	382
3	Axicabtagene CiloleuceL in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity. <i>Journal of Clinical Oncology</i> , 2020, 38, 3095-3106.	0.8	216
4	Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 1997-2007.	0.8	170
5	Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1163-1171.	2.0	105
6	Evaluating Cell-of-Origin Subtype Methods for Predicting Diffuse Large B-Cell Lymphoma Survival: A Meta-Analysis of Gene Expression Profiling and Immunohistochemistry Algorithms. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 460-467.e2.	0.2	86
7	Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era. <i>Journal of Clinical Oncology</i> , 2019, 37, 471-480.	0.8	74
8	Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412. <i>Journal of Clinical Oncology</i> , 2021, 39, 1329-1338.	0.8	60
9	Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1859-1868.	2.0	58
10	Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma: a real-world study. <i>Hematological Oncology</i> , 2017, 35, 528-535.	0.8	56
11	Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies. <i>American Journal of Hematology</i> , 2017, 92, 161-170.	2.0	56
12	Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2091-2099.	2.0	55
13	Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission. <i>Blood</i> , 2022, 139, 1330-1339.	0.6	52
14	Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma. <i>Cancer</i> , 2016, 122, 2356-2363.	2.0	51
15	Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. <i>Blood</i> , 2022, 139, 413-423.	0.6	50
16	Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival. <i>Cancer</i> , 2014, 120, 1677-1685.	2.0	49
17	Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1543-1551.	2.0	42
18	Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy. <i>Cancer</i> , 2018, 124, 2306-2315.	2.0	40

#	ARTICLE	IF	CITATIONS
19	Impact of Pretransplantation 18F-fluorodeoxy Glucoseâ€”Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1605-1611.	2.0	39
20	De novo <sc>CD</sc>5+ diffuse large <sc>B</sc>â€”cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort. <i>American Journal of Hematology</i> , 2016, 91, 395-399.	2.0	39
21	Title: A Phase I Study with an Expansion Cohort of the Combination of Ipilimumab and Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412 Arms D and E). <i>Blood</i> , 2016, 128, 1106-1106.	0.6	34
22	Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. <i>Journal of Hematology and Oncology</i> , 2019, 12, 6.	6.9	29
23	Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics. <i>Blood Advances</i> , 2020, 4, 253-262.	2.5	29
24	Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. <i>Blood Advances</i> , 2021, 5, 1648-1659.	2.5	28
25	Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2022, 40, 3020-3031.	0.8	26
26	Preliminary Safety and Efficacy of the Combination of Brentuximab Vedotin and Ipilimumab in Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412). <i>Blood</i> , 2015, 126, 585-585.	0.6	25
27	Nivolumab for Newly Diagnosed Advanced-Stage Classical Hodgkin Lymphoma (cHL): Results from the Phase 2 Checkmate 205 Study. <i>Blood</i> , 2017, 130, 651-651.	0.6	25
28	Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study. <i>Lancet Haematology</i> , 2022, 9, e289-e300.	2.2	24
29	Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts. <i>Journal of Clinical Oncology</i> , 2023, 41, 541-554.	0.8	23
30	Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 3525-3527.	0.8	22
31	Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy. <i>Blood Advances</i> , 2021, 5, 5179-5189.	2.5	21
32	Complex Karyotype Is Associated With Aggressive Disease and Shortened Progression-Free Survival in Patients With Newly Diagnosed Mantle Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 278-285.e1.	0.2	19
33	Outcomes in patients with aggressive Bâ€”cell nonâ€”Hodgkin lymphoma after intensive frontline treatment failure. <i>Cancer</i> , 2020, 126, 293-303.	2.0	18
34	Current Approaches to Mantle Cell Lymphoma: Diagnosis, Prognosis, and Therapies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 512-525.	1.8	16
35	The association of physical activity before and after lymphoma diagnosis with survival outcomes. <i>American Journal of Hematology</i> , 2018, 93, 1543-1550.	2.0	16
36	Next-generation surveillance strategies for patients with lymphoma. <i>Future Oncology</i> , 2015, 11, 1977-1991.	1.1	15

#	ARTICLE	IF	CITATIONS
37	Evaluation and Management of Lymphoma and Leukemia in Pregnancy. <i>Clinical Obstetrics and Gynecology</i> , 2011, 54, 556-566.	0.6	14
38	Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2018, 59, 2862-2870.	0.6	13
39	Racial and Socioeconomic Disparities in Mantle Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e312-e320.	0.2	13
40	Optimal disease surveillance strategies in non-Hodgkin lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2014, 2014, 481-487.	0.9	12
41	A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2015, 171, 539-546.	1.2	12
42	Role of allogeneic stem cell transplantation in mantle cell lymphoma. <i>European Journal of Haematology</i> , 2015, 94, 290-297.	1.1	11
43	Surveillance imaging in mantle cell lymphoma in first remission lacks clinical utility. <i>Leukemia and Lymphoma</i> , 2018, 59, 888-895.	0.6	11
44	Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma. <i>Blood Advances</i> , 2021, 5, 3623-3632.	2.5	11
45	Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era. <i>American Journal of Hematology</i> , 2021, 96, 1374-1384.	2.0	11
46	GIFT4 fusokine converts leukemic B cells into immune helper cells. <i>Journal of Translational Medicine</i> , 2016, 14, 106.	1.8	9
47	A Clinician's Approach to Double-Hit Lymphoma: Identification, Evaluation, and Management. <i>Journal of Oncology Practice</i> , 2016, 12, 232-238.	2.5	9
48	Novel therapies for relapsed/refractory aggressive lymphomas. <i>Hematology American Society of Hematology Education Program</i> , 2018, 2018, 75-82.	0.9	9
49	Outcomes Following Early Relapse in Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2019, 134, 753-753.	0.6	9
50	Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes. <i>Blood Advances</i> , 2022, 6, 1350-1360.	2.5	9
51	Gemcitabine and bendamustine is a safe and effective salvage regimen for patients with recurrent/refractory Hodgkin lymphoma: Results of a phase I/II study. <i>Cancer</i> , 2020, 126, 1235-1242.	2.0	8
52	Surveillance imaging during first remission in follicular lymphoma does not impact overall survival. <i>Cancer</i> , 2021, 127, 3390-3402.	2.0	6
53	Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2021, 195, 757-763.	1.2	5
54	Dose Finding Study of Ibrutinib and Venetoclax in Relapsed or Refractory Mantle Cell Lymphoma. <i>Blood Advances</i> , 2021, , .	2.5	5

#	ARTICLE	IF	CITATIONS
55	Diagnostic retinal biopsy in the management of secondary non-CNS vitreoretinal lymphoma masquerading as viral retinitis: a case report. <i>International Journal of Retina and Vitreous</i> , 2021, 7, 58.	0.9	5
56	Combination of GM-CSF With Fludarabine-Containing Regimens in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 514-518.	0.2	4
57	A phase 2 trial of alisertib in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 2268-2269.	0.6	4
58	When to use stem cell transplant in mantle cell lymphoma. <i>Expert Review of Hematology</i> , 2019, 12, 207-210.	1.0	4
59	Management of Older Adults with Mantle Cell Lymphoma. <i>Drugs and Aging</i> , 2020, 37, 469-481.	1.3	4
60	Phase II Study of Venetoclax in Combination with Obinutuzumab and Bendamustine in Patients with High Tumor Burden Follicular Lymphoma As Front Line Therapy (PrECOG 0403). <i>Blood</i> , 2021, 138, 814-814.	0.6	4
61	Hearing Loss due to Infiltration of the Tympanic Membrane by Chronic Lymphocytic Leukemia. <i>Case Reports in Hematology</i> , 2012, 2012, 1-3.	0.3	3
62	Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin. <i>Leukemia and Lymphoma</i> , 2019, 60, 940-946.	0.6	3
63	Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival. <i>European Journal of Haematology</i> , 2021, 107, 301-310.	1.1	3
64	Sequencing of Novel Therapies for Mantle Cell Lymphoma. <i>Current Treatment Options in Oncology</i> , 2021, 22, 118.	1.3	3
65	A multicenter, real-world analysis of primary central nervous system lymphoma in those with and without human immunodeficiency virus. <i>EJHaem</i> , 0, , .	0.4	3
66	Is Limited-Stage Mantle Cell Lymphoma Curable and How Is It Best Managed?. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 849-859.	0.9	2
67	Initial Treatment of Early Stage and Low Tumor Burden Follicular Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 663-672.	0.9	2
68	Preliminary Clinical Results of a Phase 1 Study Evaluating the Safety and Anti-Tumor Activity of ACTR707 in Combination with Rituximab in Subjects with Relapsed or Refractory CD20+ B-Cell Lymphoma. <i>Blood</i> , 2018, 132, 2966-2966.	0.6	2
69	Managing Relapsed Mantle Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, , .	0.2	2
70	Evaluation of All Cause of Death after High Dose Chemotherapy and Autologous Stem Cell Transplant in Hodgkin Lymphoma and Non-Hodgkin Lymphoma. <i>Blood</i> , 2018, 132, 2157-2157.	0.6	1
71	Somatic Hypermutation in Mantle Cell Lymphoma. <i>Blood</i> , 2011, 118, 5189-5189.	0.6	1
72	Clinical Validation of MCL35 in Mantle Cell Lymphoma Patients ≥65 Years Receiving Bendamustine-Rituximab. <i>Blood</i> , 2021, 138, 3517-3517.	0.6	1

#	ARTICLE	IF	CITATIONS
73	Prognostic Value of Early PET in Patients with Aggressive Non-Hodgkin Lymphoma Treated with Anti-CD19 CAR T-Cell Therapy. <i>Blood</i> , 2021, 138, 886-886.	0.6	1
74	Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI), a Novel Comorbidity Measure, Predicts Outcomes in the Context of Targeted Agents and in a Large National Registry. <i>Blood</i> , 2021, 138, 2637-2637.	0.6	1
75	Practice Patterns Pre-CART for Aggressive B-Cell Lymphomas: Patient Selection and Real World Salvage and Bridging Practices. <i>Blood</i> , 2021, 138, 532-532.	0.6	1
76	Bendamustine, Obinutuzumab and Venetoclax As Induction Therapy for Untreated Mantle Cell Lymphoma. <i>Blood</i> , 2020, 136, 33-34.	0.6	1
77	Management of Relapsed Mantle Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S98-S100.	0.2	0
78	The Prognostic Value of FDG PET/CT Prior to Autologous Stem Cell Transplant in Mantle Cell Lymphoma. <i>Blood</i> , 2011, 118, 3113-3113.	0.6	0
79	Deferred Treatment Is Associated with Improved Overall Survival in Patients with Newly Diagnosed Mantle Cell Lymphoma. <i>Blood</i> , 2015, 126, 2717-2717.	0.6	0
80	Suvmax in 18-Fluorodeoxyglucose PET/CT Potentially Predict the Estimation of a Positive Biopsy in Cases of Lymphoma. <i>Blood</i> , 2015, 126, 5043-5043.	0.6	0
81	Discontinuation Due to Toxicity Limits Treatment Duration of BTK Inhibitors in Non-Hodgkin Lymphoma. <i>Blood</i> , 2021, 138, 4685-4685.	0.6	0
82	Understanding Factors That Determine Clinical Trial Enrollment for African American Patients with Lymphoma. <i>Blood</i> , 2021, 138, 4965-4965.	0.6	0
83	A Multicenter, Real World Analysis of Primary Central Nervous System Lymphoma in Those with and without Human Immunodeficiency Virus. <i>Blood</i> , 2021, 138, 1457-1457.	0.6	0
84	Evaluation of Eligibility Criteria in First-Line Clinical Trials for Follicular Lymphoma: A MER/LEO Database Analysis. <i>Blood</i> , 2021, 138, 338-338.	0.6	0
85	Genomic and Transcriptional Characterization of Primary Mediastinal Large B Cell Lymphoma. <i>Blood</i> , 2021, 138, 2398-2398.	0.6	0
86	Ixazomib with or without Rituximab Following Immunochemotherapy and Autologous Stem Cell Transplant in Mantle Cell Lymphoma. <i>Blood</i> , 2020, 136, 39-39.	0.6	0
87	Evaluating Outcomes for Autologous Hematopoietic Cell Transplantation for Diffuse Large B-Cell Lymphoma in the CAR-T Era. <i>Blood</i> , 2020, 136, 20-21.	0.6	0
88	Medical Simulation in Relapsed Follicular Lymphoma Improves Clinical Decision Making of Hematologists/Oncologists. <i>Blood</i> , 2020, 136, 33-34.	0.6	0
89	The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI) Predicts Survival and Tolerance of Ibrutinib Therapy in Patients with CLL: A Multicenter Retrospective Cohort Study. <i>Blood</i> , 2020, 136, 1-3.	0.6	0
90	Beyond Mortality: Health-Related Quality of Life in Adolescent and Young Adult Patients with Lymphoma: A Longitudinal Study. <i>Blood</i> , 2020, 136, 7-8.	0.6	0

#	ARTICLE	IF	CITATIONS
91	Peripheral T-cell lymphoma: what's the role for transplant?. Oncology, 2013, 27, 891-2.	0.4	0